Nicotinic Acid for the Treatment of Alzheimer's Disease
Eligible age
60–85 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Increased dietary intake of niacin is correlated with reduced risk of Alzheimer's Disease and age-associated cognitive decline. The goal of this study is to collect data on the penetration of commercially available, FDA approved, extended-release niacin into the spinal fluid. One dose of 500 mg nicotinic acid will be used (in addition to placebo) to build a dose response curve for this compound in human cerebrospinal fluid. This objective will demonstrate target engagement of HCAR2 in the central nervous system, after oral treatment with niacin. The primary endpoints are to show increased nicotinic acid levels in blood and cerebrospinal fluid. A secondary endpoint is to collect safety and tolerability data of niacin in this particular population.
Sponsor: Indiana University
You may qualify if…
- ✓ Age 60-85 males or females
- ✓ Clinically have a diagnosis of Alzheimer's disease in the mild-moderate dementia range Mini Mental Status Examination (MMSE) between 14-24 inclusive
- ✓ Must be on a stable dose (30 days minimum) of a cholinesterase inhibitor and/or memantine (or absence thereof)
- ✓ Have a reliable co-participant who has at least 3 days of face-to-face contact per week with the patient and ensures medical compliance with the study drug.
- ✓ Neuroimaging (MRI or CT scan of the brain) should be available within 1 year of screening
You may not qualify if…
- ✕ Any contraindication to clinical lumbar puncture including increased intracranial pressure, posterior fossa mass, bleeding diathesis, use of antiplatelet medications other than aspirin, use of any anticoagulant
- ✕ Severe cerebrovascular disease
- ✕ History of large territory stroke
- ✕ Allergy or sensitivity to B-vitamins or nicotinic acid
- ✕ History of elevated liver function tests (ALT/AST \> 2x the upper limit of normal) or known liver disease
- ✕ Current consumption of Vitamin B3 (any form, including nicotinic acid) - including multivitamins and energy drinks. Participants taking a supplement containing Niacin must washout for 4 weeks prior to screening to participate.
- ✕ Renal impairment of Stage 2 or greater
Where it's recruiting
Indianapolis
Source: ClinicalTrials.gov · NCT06582706 · last updated 2026-03-05